All News

People recently diagnosed with cancer may be at an increased risk of contracting COVID-19 and experiencing worse outcomes than those who have never had a cancer diagnosis. The association was heightened in Black patients.

The National Comprehensive Cancer Network (NCCN) recommends that patients receiving active cancer treatment get the COVID-19 vaccine.

A simple quote reminds a cancer survivor of what is important for every one of us to remember.

Combination treatment with Opdivo and Yervoy may have better overall survival rates for patients with metastatic uveal melanoma.

CURE® compiled a roundup of several recent news and updates involving quality of life improvements that patients with cancer may have missed.

CURE® compiled a roundup of five recent pieces of COVID-19 news and updates that patients with cancer may have missed.

After a fast-track designation, the Food and Drug Administration approved the combination of Cabometyx and Opdivo in the firstline setting for patients with advanced or metastatic renal cell carcinoma.

The priority review will focus on retifanlimab for the treatment of certain adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who did not tolerate platinum-based chemotherapy. Currently, according to Incyte, there are no approved treatments for this patient population.

With a terminal illness of metastatic breast cancer, I qualify for Social Security Disability as the COVID-19 pandemic has retired me, but that isn't stopping me from achieving my life goals.

From a Marine veteran walking 8,500 miles over the last 24 years to raise cancer awareness and funds for treatment to researchers using cancer cells from a deceased osteosarcoma donor to help advance treatment, here’s what’s happening in the cancer landscape this week.

Women who reported using oral contraceptives had a decreased risk of endometrial and ovarian cancer, compared to those who never used the hormone medications. The data also indicated the association extended up to three decades after patients stopped using the contraceptives.

SWORD Performance Hydration is a natural drink that helps to hydrate and energize individuals, and could even assist with some toxicities that are a result from chemotherapy.

“Along with a tolerable safety profile and supportive quality of life, these final efficacy results demonstrate the clinical benefit of (Tibsovo) in (previously treated patients with IDH1-mutant cholangiocarcinoma), for which there is an urgent need for new therapies,” said an expert from Massachusetts General Hospital, who presented the data.

It's important for cancer survivors to recognize the major milestones and anniversaries in their cancer journey. Even if it's an anniversary they didn't want.

This week on the “CURE® Talks Cancer” podcast, we spoke with Martha Raymond, of The Raymond Foundation, about how providers can ensure patient safety to increase trial enrollment during the COVID-19 pandemic, and what she and her colleagues are doing to provide better trial access to all patients with cancer.

For patients with gastric/ gastroesophageal cancer, treatment with Bavencio after chemotherapy shows favorable safety, but no overall survival improvement.

Clinical trials may seem scary and challenging for patients with cancer, but in reality, they don’t have to be. Here is how talking to former patients on clinical trials can help.

Findings from a study focused on patient-reported experiences, found that aching joints, aching muscles and fatigue were more common than initially found in clinical trials.

Appointment fatigue is a real thing for patients with cancer and even survivors, but there are ways to overcome it.

The priority review will focus on Opdivo with chemotherapy for the treatment several gastrointestinal cancers, which has recently become a rising area in novel treatment development.

The combination of Inlyta (axitinib) and the synthetic hormone octreotide acetate failed to significantly improve progression-free survival, compared to placebo with the synthetic hormone. However, the results indicated the Inlyta-based combination did improve disease response in patients versus the placebo-based combination.

In the final analysis of the phase 2 TASCO1 trial, patients within the Lonsurf and Avastin arm reached a median overall survival of 22.31 months compared with 17.67 months in the Xeloda and Avastin arm.

“This is the longest survival seen in a phase 3 study of advanced liver cancer,” lead study author Dr. Richard S. Finn, of the UCLA Jonsson Comprehensive Cancer Center, said in a virtual presentation of the data.

The balancing act of being a caregiver and parent simultaneously is one that requires acceptance and fierceness.

The data in the study presented at the ASCO Gastrointestinal Cancers Symposium demonstrated that while rare, stage 4 gastrointestinal stromal tumors often spread to the liver.

A group of patients with gastrointestinal cancers reported that a novel artificial intelligence-based search tool made it easier for them to find and understand cancer clinical trials. The tool, according to study authors, would not only help with trial accrual, but could also help improve trial diversity.

The Food and Drug Administration has had a busy winter so far, approving several new agents to treat a variety of cancers. Here are seven recent approvals that patients with cancer may have missed.

As a cancer survivor, I’ve found many reasons to celebrate. Here’s one more.

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.